We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma.
- Authors
Hyung, Jaewon; Hong, Jung Yong; Yoon, Dok Hyun; Kim, Shin; Park, Jung Sun; Park, Chan-sik; Lee, Sang-wook; Kim, Jeong Hoon; Ryu, Jin Sook; Huh, Jooryung; Suh, Cheolwon
- Abstract
Primary central nervous system lymphoma (PCNSL) is a rare extranodal non-Hodgkin lymphoma for which standard treatment has yet to be established. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a suitable consolidation strategy for patients who respond to induction chemotherapy. The purpose of this study was to compare the outcome and toxicity profile of the combination of busulfan, cyclophosphamide, and etoposide (BuCyE) with that of the combination of thiotepa, busulfan, and cyclophosphamide (TBC) as conditioning regimens of upfront ASCT for consolidation therapy in PCNSL. The PCNSL registry data set, prospectively collected from March 1993 to May 2017 at Asan Medical Center, was reviewed retrospectively. Patients with objective response to induction chemotherapy who received BuCyE or TBC as conditioning regimen for ASCT were included in the analysis. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Among 241 patients with a diagnosis of PCNSL, 53 received ASCT as upfront consolidation therapy with TBC (28 patients) or BuCyE (25 patients) as conditioning regimen. No median OS or PFS was reached in the TBC group, while the BuCyE group reached a median OS of 4.9 years (p = 0.02) and median PFS of 1.1 years (p = 0.007). The incidence of oral mucositis, nausea, and vomiting was higher with TBC than BuCyE. The median admission duration and days to engraftment were similar between the two groups. Despite the greater incidence of adverse events, TBC showed better outcomes than BuCyE in terms of survival.
- Subjects
STEM cell transplantation; CENTRAL nervous system; BUSULFAN; CANCER chemotherapy; THERAPEUTICS
- Publication
Annals of Hematology, 2019, Vol 98, Issue 7, p1657
- ISSN
0939-5555
- Publication type
journal article
- DOI
10.1007/s00277-019-03667-1